Quotient Limited; Ortho Clinical Diagnostics
Quotient and Ortho Clinical Diagnostics to Present Symposium on Role of Extended Phenotyping in Blood Matching at ISBT
EYSINS, SWITZERLAND and RARITAN, NJ--(Marketwired - Jun 20, 2017) - Quotient Limited (
"The symposium will feature expert perspectives on the limitations of current immunohematology, or blood-matching, practices and potential changes that could dramatically influence future standards of care in transfusion medicine," said Heidi Casaletto, vice president of Transfusion Medicine at Ortho.
"Better matching of donor units to patients is imperative in reducing alloimmunization during transfusions. Alloimmunization poses a threat to patient safety as well as compatibility issues in subsequent transfusions, resulting in a significant economic impact on blood establishments and hospitals," added Paul Cowan, chairman and chief executive officer at Quotient.
- Dr. Jonathan Wallis, Newcastle Hospital, UK: "Antibodies and the Haematology Patient"
- Dr. Jill Storry, Lund University, Sweden: "Strategies to Provide Phenotyped Blood from a Blood Centre"
- Prof. David Roberts, John Radcliffe Hospital, University of Oxford, UK: "The Future of Blood Group Matching"
During the symposium, which will be moderated by Dr. Geoffrey David Poole (an external consultant for Ortho), speakers will address the role of extended phenotyping to better match donor units to patients, reducing the risk of alloimmunization. They will also share examples of patient matching and advanced donor identification initiatives they have implemented.
Quotient will also be exhibiting at the Congress (booth no. C3.418).
New Solutions for the Global Transfusion Diagnostics Market
In January 2015, Quotient and Ortho announced an agreement to bring MosaiQ™, an innovative transfusion medicine diagnostic platform, to the market. The new technology promises to allow improved time to test results and more comprehensive matching of donor and patient blood, beyond what is available in current transfusion diagnostic instruments.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and donor disease screening (transfusion diagnostics), Quotient is developing its proprietary MosaiQ™ technology platform to disrupt and transform the $3.4 billion global transfusion diagnostics market. Quotient has over 30 years of experience developing, manufacturing and commercializing transfusion diagnostic products. The company's operations are based in Switzerland, Scotland and the US. For more information, visit: www.quotientbd.com .
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 120 countries, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com .
Information om Marketwired
Følg pressemeddelelser fra Marketwired
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Marketwired
Bombardier Transportation15.5.2018 02:51 | pressemeddelelse
Bombardier's Real-Time Passenger Load Display Software Solution Launches in Singapore
Bombardier Inc.3.5.2018 22:49 | pressemeddelelse
Bombardier Announces the Election of its Board of Directors, Pays Tribute to Former CEO and Chairman Laurent Beaudoin
Bombardier Inc.3.5.2018 14:04 | pressemeddelelse
Bombardier Reports First Quarter 2018 Results, Announces Sale of Downsview Property and plans for new Centre of Excellence for Global Aircraft
Bombardier Inc.2.5.2018 16:22 | pressemeddelelse
REMINDER/Media Advisory: Bombardier to Report its First Quarter 2018 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 3
Bombardier Inc.23.4.2018 22:11 | pressemeddelelse
Media Advisory: Bombardier to Report its First Quarter 2018 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 3
Bombardier Transportation18.4.2018 16:08 | pressemeddelelse
Bombardier Signs Long-Term Maintenance Contract for Melbourne's First High-Capacity Signalling System
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum